Compare Merck & Co., Inc. (MRK) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs WD 40 Company — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while WD 40 Company trades at $199.54 (market cap $2.71B). The key difference: Merck & Co., Inc. is far larger — about 135.2× WD 40 Company's market cap, and Merck & Co., Inc. pays the higher dividend (2.29%). Which is the better fit depends on your goals.
| MRK | WDFC | |
|---|---|---|
Market Cap | $366.28B | $2.71B |
Sector | Health | Technology |
52-Week High | $156.43 | $264.91 |
52-Week Low | $77.60 | $187.52 |
Enterprise Value | $413.04B | $2.76B |
Dividend Yield | 2.29% | 2.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
WDFC trades at $201.73, down 2.81% today, with a bearish technical signal but strong fundamentals. Recent earnings show mixed results with a Q4 2025 miss but Q1 and Q2 2026 beats. The company maintains robust profitability with a 55.82% gross margin and 13.22% net margin. News highlights strong Q3 2026 performance and strategic growth initiatives including global expansion and digital transformation.
Outlook is cautiously optimistic with solid brand loyalty and growth potential, but risks include input cost pressures and valuation concerns. Analyst consensus is mixed with a 'Hold' majority. The stock's current price near support at $199 suggests potential stability if fundamentals hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
